How Effective is the Annual Flu Vaccine Program?

PS Dr. Robert Malone: The Annual Flu Vaccine Program Is ‘Built on a Lie’

Vaccine Effectiveness

Flu vaccine effectiveness can change from year to year.
At the time of writing this article, the 2020–2021 flu season is underway.
In the coming months, scientists will begin to get estimates of the effectiveness of the 2020–2021 flu vaccine.

However, the CDCTrusted Source does currently have information about the estimated effectiveness of the vaccines from past flu seasons.

The chart below shows the effectiveness of the flu vaccine for the previous five flu seasons.

Does flu vaccine effectiveness differ across age groups?

It’s possible that there can be some variance in the effectiveness of the vaccine between different age groups. The CDC tracks this data as well as data on the flu’s overall effectiveness.

Here’s a look at the effectiveness estimates for all vaccine types across different age groups from the past five flu seasons, according to the CDC.

When looking at vaccine effectiveness studies, it’s important to remember that the results can be influenced by several factors.
These factors can include the population studied, the specific flu season, and how the study was conducted.

When looking at flu vaccines history, it is obvious that it has been neverending “moving target”.
Covid p(l)andemic became perfect excuse for imposing (by the Elites) never ending lockdowns, restrictions, surveillance (contact tracing), coerced testing and vaccination programs – until population is reduced as per agenda (see the Georgia Guidestones).

Serious Adverse effects of COVID vaccination

Source: CDC.GOV post: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html

For public awareness and in the interest of transparency, CDC is providing timely updates on the following serious adverse events of interest:

• Anaphylaxis after COVID-19 vaccination is rare and has occurred in approximately 2 to 5 people per million vaccinated in the United States. Severe allergic reactions, including anaphylaxis, can occur after any vaccination. If this occurs, vaccination providers can effectively and immediately treat the reaction. Learn more about COVID-19 vaccines and allergic reactions, including anaphylaxis.
• Thrombosis with thrombocytopenia syndrome (TTS) after Johnson & Johnson’s Janssen (J&J/Janssen) COVID-19 vaccination is rare. As of July 12, 2021, more than 12.8 million doses of the J&J/Janssen COVID-19 Vaccine have been given in the United States. CDC and FDA identified 38 confirmed reports of people who got the J&J/Janssen COVID-19 Vaccine and later developed TTS. Women younger than 50 years old especially should be aware of the rare but increased risk of this adverse event. There are other COVID-19 vaccine options available for which this risk has not been seen. Learn more about J&J/Janssen COVID-19 Vaccine and TTS.
  • To date, two confirmed cases of TTS following mRNA COVID-19 vaccination (Moderna) have been reported to VAERS after more than 321 million doses of mRNA COVID-19 vaccines administered in the United States. Based on available data, there is not an increased risk for TTS after mRNA COVID-19 vaccination.
• CDC and FDA are monitoring reports of Guillain-Barré Syndrome (GBS) in people who have received the J&J/Janssen COVID-19 Vaccine. GBS is a rare disorder where the body’s immune system damages nerve cells, causing muscle weakness and sometimes paralysis. Most people fully recover from GBS, but some have permanent nerve damage. After 12.8 million J&J/Janssen COVID-19 Vaccine doses administered, there have been around 100 preliminary reports of GBS identified in VAERS. These cases have largely been reported about 2 weeks after vaccination and mostly in men, many 50 years and older. CDC will continue to monitor for and evaluate reports of GBS occurring after COVID-19 vaccination and will share more information as it becomes available.
• Myocarditis and pericarditis after COVID-19 vaccination are rare. As of July 12, 2021, VAERS has received 1,047 reports of myocarditis or pericarditis among people ages 30 and younger who received a COVID-19 vaccine. Most cases have been reported after mRNA COVID-19 vaccination (Pfizer-BioNTech or Moderna), particularly in male adolescents and young adults. Through follow-up, including medical record reviews, CDC and FDA have confirmed 633 reports of myocarditis or pericarditis. CDC and its partners are investigating these reports to assess whether there is a relationship to COVID-19 vaccination. Learn more about COVID-19 vaccines and myocarditis.
• Reports of death after COVID-19 vaccination are rare. More than 334 million doses of COVID-19 vaccines were administered in the United States from December 14, 2020, through July 12, 2021. During this time, VAERS received 6,079 reports of death (0.0018%) among people who received a COVID-19 vaccine. FDA requires healthcare providers to report any death after COVID-19 vaccination to VAERS, even if it’s unclear whether the vaccine was the cause. Reports of adverse events to VAERS following vaccination, including deaths, do not necessarily mean that a vaccine caused a health problem. A review of available clinical information, including death certificates, autopsy, and medical records, has not established a causal link to COVID-19 vaccines. However, recent reports indicate a plausible causal relationship between the J&J/Janssen COVID-19 Vaccine and TTS, a rare and serious adverse event—blood clots with low platelets—which has caused deaths.

Vaccine Adverse Event Reporting System (VAERS)

PS  A Case of Predictive Programming?